In the pivotal phase 3 efficacy trial (NCT02747927) of the TAK-003 dengue vaccine, 5 of 13,380 TAK-003 recipients and 13 of 6,687 placebo recipients experienced two episodes of symptomatic dengue between the first dose and the end of the study, ∼57 months later (patients received the second dose 3 months after the first dose). Two of these participants experienced repeat infection with the same serotype (i.e., homotypic reinfection). In comparison with placebo, the relative risk of a subsequent episode of symptomatic dengue was 0.19 (95% CI, 0.07-0.54) in TAK-003 recipients. Based on the small number of subsequent episodes, these data suggest a potential incremental effect of TAK-003 beyond prevention of the first episode of symptomatic dengue after vaccination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10077010 | PMC |
| http://dx.doi.org/10.4269/ajtmh.22-0673 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Development and optimization of an mRNA-vectored single-chain IgA1 isotype monoclonal antibody with potential to treat or prevent dengue virus infection.
Antiviral Res
January 2025
Department of Microbiology and Immunology, State University of New York Upstate Medical University, Syracuse, NY 13210, USA; Institute for Global Health and Translational Sciences, State University of New York Upstate Medical University, Syracuse, NY 13210, USA. Electronic address:
Dengue virus (DENV) is a rapidly expanding infectious disease threat that causes an estimated 100 million symptomatic infections every year. A barrier to preventing DENV infections with traditional vaccines or prophylactic monoclonal antibody (mAb) therapies is the phenomenon of Antibody-Dependent Enhancement (ADE), wherein sub-neutralizing levels of DENV-specific IgG antibodies can enhance infection and pathogenesis rather than providing protection from disease. Fortunately, IgG is not the only antibody isotype capable of binding and neutralizing DENV, as DENV-specific IgA1 isotype mAbs can bind and neutralize DENV while without exhibiting any ADE activity.
View Article and Find Full Text PDFThe 2023 Dengue Outbreak in Lombardy, Italy: A One-Health Perspective.
Travel Med Infect Dis
January 2025
General Directorate of Welfare, Regione Lombardia, Milano, Italy.
Introduction: Here we reported the virological, entomological and epidemiological characteristics of the large autochthonous outbreak of dengue (DENV) occurred in a small village of the Lombardy region (Northern Italy) during summer 2023.
Methods: After the diagnosis of the first autochthonous case on 18 August 2023, public health measures, including epidemiological investigation and vector control measures, were carried out. A serological screening for DENV antibodies detection was offered to the population.
Zika virus infections and associated risk factors among pregnant women in Gombe, Nigeria.
Virol Sin
December 2024
Department of Medical Laboratory Science, University of Maiduguri, College of Medical Sciences, P.M.B. 1069, Maiduguri, Nigeria. Electronic address:
Article Synopsis
- In-utero exposure to Zika virus (ZIKV) can result in severe outcomes like miscarriage and congenital Zika syndrome, prompting a study on the infection rates among pregnant women from February to April 2022.
- Researchers tested 200 pregnant women for ZIKV antibodies and found that 16.5% had ZIKV IgM, 10% had IgG, and 23% had neutralizing antibodies, indicating various stages of infection and immunity.
- The study also revealed that recent ZIKV infections were more common in sexually active women aged 20-29, with higher infection risks in first trimester and grand-multiparous women, although no significant link was found between ZIKV and specific pregnancy trimest
Analysis of Liver Function Tests in Dengue Infected Patients.
Mymensingh Med J
January 2025
Dr Sadia Khanduker, Associate Professor, Department of Biochemistry, Bangladesh Medical College, Dhaka, Bangladesh; E-mail:
Dengue is a mosquito-borne infection that in recent years has become a vital disease of international public health concern. Dengue virus infections and illness when symptomatic, that patients tend to present with a significantly wide variety manifestation. The aim of the study was to gauge liver dysfunction in patients with dengue infections.
View Article and Find Full Text PDFThe importance of paying attention to the role of lipid-lowering drugs in controlling dengue virus infection.
Virol J
December 2024
Department of Clinical Pharmacy, Faculty of Pharmacy, Islamic Azad University of Medical Sciences, Tehran, Iran.
The Flaviviridae family includes the dengue virus (DENV). About half of the world's population is in danger because of the estimated 390 million infections and 96 million symptomatic cases that occur each year. An effective treatment for dengue fever (DF) does not yet exist.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!